Serum biomarkers of vascular cognitive impairment evaluated by bead-based proteomic technology

Xi, Liu; Zhang, Junjian; Liu, Yumin; Yunwen, Luo; Wen, Haoran

doi:10.1016/j.neulet.2009.07.056

Cited by 14 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A relationship between apolipoproteins and the development of pulmonary arterial hypertension in sickle cell disease was established by MALDI (Yuditskaya et al, 2009). Peptides from trace-amine associated receptor 6 (TAAR6) were reported to differ between control and vascular cognitive impairment (Xi et al, 2009). The identification and one-way ANOVA analysis of fragments from serum by MALDI were prognostic of melanoma survival .…”

Section: E Analysis Of Identified Polypeptidesmentioning

confidence: 99%

Mass spectrometry of peptides and proteins from human blood

Zhu

Bowden

Zhang

et al. 2010

Mass Spectrometry Reviews

View full text Add to dashboard Cite

It is difficult to convey the accelerating rate and growing importance of mass spectrometry applications to human blood proteins and peptides. Mass spectrometry can rapidly detect and identify the ionizable peptides from the proteins in a simple mixture and reveal many of their post-translational modifications. However, blood is a complex mixture that may contain many proteins first expressed in cells and tissues. The complete analysis of blood proteins is a daunting task that will rely on a wide range of disciplines from physics, chemistry, biochemistry, genetics, electromagnetic instrumentation, mathematics and computation. Therefore the comprehensive discovery and analysis of blood proteins will rank among the great technical challenges and require the cumulative sum of many of mankind's scientific achievements together. A variety of methods have been used to fractionate, analyze and identify proteins from blood, each yielding a small piece of the whole and throwing the great size of the task into sharp relief. The approaches attempted to date clearly indicate that enumerating the proteins and peptides of blood can be accomplished. There is no doubt that the mass spectrometry of blood will be crucial to the discovery and analysis of proteins, enzyme activities, and post-translational processes that underlay the mechanisms of disease. At present both discovery and quantification of proteins from blood are commonly reaching sensitivities of ∼1 ng/mL.

show abstract

Section: E Analysis Of Identified Polypeptidesmentioning

confidence: 99%

Mass spectrometry of peptides and proteins from human blood

Zhu

Bowden

Zhang

et al. 2010

Mass Spectrometry Reviews

View full text Add to dashboard Cite

show abstract

“…(2008) have identified, by means of a proteomic approach, plasma haptoglobin as a possible therapeutic marker in the early stages of stroke in spontaneously hypertensive stroke‐prone rats. Xi et al. (2009) used a proteomic approach to identify novel plasma biomarkers that could contribute to a better understanding of the processes involved in vascular cognitive impairment.…”

Section: Discussionmentioning

confidence: 99%

Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke

López‐Farré

Zamorano-León

Segura³

et al. 2012

Journal of Neurochemistry

View full text Add to dashboard Cite

J. Neurochem. (2012) 121, 314–325. Abstract Stroke patients have a high risk of vascular recurrence. Biomarkers related to vascular recurrence, however, remain to be identified. The aim of the study was to identify, through proteomic analysis, plasma biomarkers associated with vascular recurrence within one year after the first ischemic stroke. This is a substudy (n = 134) of a large prospective multicenter study of post‐stroke patients with an ischemic stroke. Plasma samples were obtained at inclusion. Among the identified proteins, only plasma levels of desmoplakin I were associated with protection against a new vascular event (Odds ratio: 0.64; 95% CI: 0.46–0.89; p = 0.009) after adjustment for hypercholesterolemia, statins and previous atherothrombotic stroke subtype. A greater number of patients without vascular recurrence had been treated with statins within three months of the recent ischemic stroke. Only patients who had been taking statins for 3 months after the ischemic stroke and did not suffer vascular recurrence over a follow‐up year, have higher levels of desmoplakin I at the time of inclusion (Odds ratio 0.49; 95% CI: 0.28–0.86; p = 0.013). Increased desmoplakin I levels, determined within 1–3 months of the first ischemic stroke, could be a biomarker for statin responsiveness against a new vascular event in post‐ischemic stroke patients taking statins early (1–3 months) after the ischemic stroke.

show abstract

“…There are several advantages to the serum MS profiling described here, especially compared with more labor intensive and technically challenging assays, such as immunohistochemistry, fluorescence in situ hybridization, and PCR, due to the unavailability of high-quality tumor specimens and intratumoral heterogeneity [8,9]. LC-MS/MS has shown promise in biomarker discovery and proved to be a useful method for detection of low abundance proteins [10], potentially allowing the selection of patients who may benefit from such therapies. Early studies using MS to develop proteomic profiles from patient serum, coupled with advanced data mining algorithms had triggered hopes that this technology could be used for cancer diagnosis, prognosis, and disease/treatment monitoring.…”

Section: Discussionmentioning

confidence: 99%

Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy

Huang¹,

Ding²,

Li³

et al. 2012

neo

View full text Add to dashboard Cite

Purpose: To find potential serum biomakers that can predict clinical outcome upon treatment in non-small cell lung cancer (NSCLC) by analyzing differential proteins in serum with different sensitivity of chemoradiotherapy (CRT).Materials and Methods: Sera were collected from 37 NSCLC patients before they were treated with concurrent cisplatinbased CRT. According to the outcome of CRT, the patients were divided into sensitive group and resistant one. The proteins in sera were separated by two-dimensional gel electrophoresis after the high abundance proteins were removed from sera. The significantly differentially expressed proteins between two groups were analyzed by liquid chromatography and tendem mass spectrometry (LC-MS/MS). Then, an additional 50 serum samples were used for ELISA analysis to validate the identified proteins that we got in the experiment.Results: Proteins in sera of each group were successfully separated on 2D gels. There were significant discrepancies in serum protein expression between NSCLC patients with different CRT sensitivity. Among eight differently expressed proteins, six proteins were successfully identified with five of which higher expressed and one lower expressed in resistant group. The increased Alpha-1-antitrypsin (α1-AT) level in resistant group comparing to sensitive one were validated by ELISA analysis (p<0.05).Conclusions: Proteomic approach may serve as a useful method in detecting the potential biomarkers for predicting the outcome of treatment in NSCLC patients. NSCLC patients with high α1-AT level in serum before CRT may have a worse treatment outcome.

show abstract

Serum biomarkers of vascular cognitive impairment evaluated by bead-based proteomic technology

Cited by 14 publications

References 32 publications

Mass spectrometry of peptides and proteins from human blood

Mass spectrometry of peptides and proteins from human blood

Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke

Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy

Contact Info

Product

Resources

About